Robert S, Poncelet P, Lacroix R, Arnaud L, Giraudo L, Hauchard A, Sampol J, Dignat-George F
Unité Mixte de Recherche S 608 (UMR-S 608), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de la Méditerranée, Marseille, France.
J Thromb Haemost. 2009 Jan;7(1):190-7. doi: 10.1111/j.1538-7836.2008.03200.x. Epub 2008 Oct 18.
Platelet microparticles (PMPs) have proved useful to identify patients with vascular risk. However, PMP counting, which is currently done by flow cytometry (FCM), needs to be standardized.
The objectives were (i) to standardize FCM settings for PMP counts on a routine instrument (Cytomics FC500) using size-calibrated fluorescent beads; (ii) to determine intra-instrument and inter-instrument reproducibility; and (iii) to establish PMP values in healthy subjects.
Using a blend of size-calibrated fluorescent beads (0.5 and 0.9 mum) in a fixed numerical ratio (Megamix), we gated PMPs in a restricted size window. To test intra-instrument and inter-instrument reproducibility, annexin V and CD41 coexpression were used to count PMPs in frozen aliquots of the same platelet-free plasma (PFP) over 4 months and in PFP from 10 healthy subjects on three independent flow cytometers.
This calibrated-bead strategy allowed full long-term control of the FCM-based microparticle protocol and reproducible PMP counts over time [coefficient of variation (CV) < 10%]. Optimal settings were easily transferred from one instrument to another, using Megamix as a stable template. Similar PMP counts (CV < 12%) were obtained using the three instruments. With such a standardized FCM protocol, PMP values were established in healthy subjects (n = 60) with significantly higher levels in women than in men [median (1st quartile to 3rd quartile): 1775 microL(-1) (1014-3039 microL(-1)) vs. 656 microL(-1) (407-962 microL(-1))].
The present strategy provides a new option for PMP count standardization and thus opens the way for multicenter studies.
血小板微粒(PMPs)已被证明有助于识别有血管风险的患者。然而,目前通过流式细胞术(FCM)进行的PMP计数需要标准化。
目标是(i)使用尺寸校准的荧光微球,在常规仪器(Cytomics FC500)上对PMP计数的FCM设置进行标准化;(ii)确定仪器内和仪器间的可重复性;以及(iii)确定健康受试者的PMP值。
使用固定数量比例(Megamix)的尺寸校准荧光微球(0.5和0.9微米)混合物,我们在受限的尺寸窗口中对PMP进行门控。为了测试仪器内和仪器间的可重复性,在4个月内对同一无血小板血浆(PFP)的冷冻等分试样以及来自10名健康受试者的PFP,使用膜联蛋白V和CD41共表达在三台独立的流式细胞仪上对PMP进行计数。
这种校准微球策略允许对基于FCM的微粒检测方案进行全面的长期控制,并随着时间的推移实现可重复的PMP计数[变异系数(CV)<10%]。使用Megamix作为稳定模板,最佳设置可轻松从一台仪器转移到另一台仪器。使用这三台仪器获得了相似的PMP计数(CV<12%)。采用这种标准化的FCM检测方案,在健康受试者(n = 60)中确定了PMP值,女性的水平显著高于男性[中位数(第1四分位数至第3四分位数):1775 μL-1(1014 - 3039 μL-1)对656 μL-1(407 - 962 μL-1)]。
本策略为PMP计数标准化提供了一种新选择,从而为多中心研究开辟了道路。